BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sørensen BS, Pawelke J, Bauer J, Burnet NG, Dasu A, Høyer M, Karger CP, Krause M, Schwarz M, Underwood TSA, Wagenaar D, Whitfield GA, Lühr A. Does the uncertainty in relative biological effectiveness affect patient treatment in proton therapy? Radiother Oncol 2021;163:177-84. [PMID: 34480959 DOI: 10.1016/j.radonc.2021.08.016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Tommasino F, Cartechini G, Righetto R, Farace P, Cianchetti M. Does variable RBE affect toxicity risks for mediastinal lymphoma patients? NTCP-based evaluation after proton therapy treatment. Physica Medica 2023;108:102569. [DOI: 10.1016/j.ejmp.2023.102569] [Reference Citation Analysis]
2 Magrin G, Palmans H, Stock M, Georg D. State-of-the-art and potential of experimental microdosimetry in ion-beam therapy. Radiother Oncol 2023;182:109586. [PMID: 36842667 DOI: 10.1016/j.radonc.2023.109586] [Reference Citation Analysis]
3 Gaito S, Hwang EJ, France A, Aznar MC, Burnet N, Crellin A, Holtzman AL, Indelicato DJ, Timmerman B, Whitfield GA, Smith E. Outcomes of Patients Treated in the UK Proton Overseas Programme: Central Nervous System Group. Clin Oncol (R Coll Radiol) 2023:S0936-6555(23)00048-1. [PMID: 36804292 DOI: 10.1016/j.clon.2023.01.024] [Reference Citation Analysis]
4 Offersen BV, Aznar MC, Bacchus C, Coppes RP, Deutsch E, Georg D, Haustermans K, Hoskin P, Krause M, Lartigau EF, Lee AWM, Löck S, Thwaites DI, van der Kogel AJ, van der Heide U, Valentini V, Overgaard J, Baumann M. The role of ESTRO guidelines in achieving consistency and quality in clinical radiation oncology practice. Radiother Oncol 2023;179:109446. [PMID: 36566990 DOI: 10.1016/j.radonc.2022.109446] [Reference Citation Analysis]
5 Eulitz J, G C Troost E, Klünder L, Raschke F, Hahn C, Schulz E, Seidlitz A, Thiem J, Karpowitz C, Hahlbohm P, Grey A, Engellandt K, Löck S, Krause M, Lühr A. Increased relative biological effectiveness and periventricular radiosensitivity in proton therapy of glioma patients. Radiother Oncol 2023;178:109422. [PMID: 36435337 DOI: 10.1016/j.radonc.2022.11.011] [Reference Citation Analysis]
6 Azcona J, Aguilar B, Perales Á, Polo R, Zucca D, Irazola L, Viñals A, Cabello P, Delgado J, Pedrero D, Bermúdez R, Fayos-solá R, Huesa-berral C, Burguete J. Commissioning of a synchrotron-based proton beam therapy system for use with a Monte Carlo treatment planning system. Radiation Physics and Chemistry 2022. [DOI: 10.1016/j.radphyschem.2022.110708] [Reference Citation Analysis]
7 Shin E, Kim D, Choi YY, Youn H, Seong KM, Youn B. LDR-adapted liver-derived cytokines have potential to induce atherosclerosis. International Journal of Radiation Biology 2022. [DOI: 10.1080/09553002.2023.2145028] [Reference Citation Analysis]
8 Hahn C, Heuchel L, Ödén J, Traneus E, Wulff J, Plaude S, Timmermann B, Bäumer C, Lühr A. Comparing biological effectiveness guided plan optimization strategies for cranial proton therapy: potential and challenges. Radiat Oncol 2022;17:169. [PMID: 36273132 DOI: 10.1186/s13014-022-02143-x] [Reference Citation Analysis]
9 Underwood TSA, McNamara AL, Appelt A, Haviland JS, Sørensen BS, Troost EGC. A systematic review of clinical studies on variable proton Relative Biological Effectiveness (RBE). Radiother Oncol 2022;175:79-92. [PMID: 35988776 DOI: 10.1016/j.radonc.2022.08.014] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Pelak MJ, Flechl B, Hug E, Galalae R, Konrath L, Góra J, Fossati P, Lütgendorf-caucig C, Tubin S, Konstantinovic R, Mock U, Fussl C, Georg P. Normofractionated and moderately hypofractionated proton therapy: comparison of acute toxicity and early quality of life outcomes. Front Oncol 2022;12:962697. [DOI: 10.3389/fonc.2022.962697] [Reference Citation Analysis]
11 Fredrik Fjæra L, Indelicato DJ, Handeland AH, Ytre-Hauge KS, Lassen-Ramshad Y, Muren LP, Stokkevåg CH. A case-control study of linear energy transfer and relative biological effectiveness related to symptomatic brainstem toxicity following pediatric proton therapy. Radiother Oncol 2022:S0167-8140(22)04220-7. [PMID: 35917900 DOI: 10.1016/j.radonc.2022.07.022] [Reference Citation Analysis]
12 Heuchel L, Hahn C, Pawelke J, Sørensen BS, Dosanjh M, Lühr A. Clinical use and future requirements of relative biological effectiveness: survey among all european proton therapy centres. Radiother Oncol 2022:S0167-8140(22)00266-3. [PMID: 35605747 DOI: 10.1016/j.radonc.2022.05.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
13 Burnet NG, Mee T, Gaito S, Kirkby NF, Aitkenhead AH, Anandadas CN, Aznar MC, Barraclough LH, Borst G, Charlwood FC, Clarke M, Colaco RJ, Crellin AM, Defourney NN, Hague CJ, Harris M, Henthorn NT, Hopkins KI, Hwang E, Ingram SP, Kirkby KJ, Lee LW, Lines D, Lingard Z, Lowe M, Mackay RI, McBain CA, Merchant MJ, Noble DJ, Pan S, Price JM, Radhakrishna G, Reboredo-Gil D, Salem A, Sashidharan S, Sitch P, Smith E, Smith EA, Taylor MJ, Thomson DJ, Thorp NJ, Underwood TS, Warmenhoven JW, Wylie JP, Whitfield G. Estimating the percentage of patients who might benefit from proton beam therapy instead of X-ray radiotherapy. Br J Radiol 2022;95:20211175. [PMID: 35220723 DOI: 10.1259/bjr.20211175] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Jones B. Risk assessment for proton therapy in the central nervous system by assuming small increments in RBE. Radiation Physics and Chemistry 2022. [DOI: 10.1016/j.radphyschem.2022.110213] [Reference Citation Analysis]
15 Hahn C, Ödén J, Dasu A, Vestergaard A, Fuglsang Jensen M, Sokol O, Pardi C, Bourhaleb F, Leite A, de Marzi L, Smith E, Aitkenhead A, Rose C, Merchant M, Kirkby K, Grzanka L, Pawelke J, Lühr A. Towards harmonizing clinical linear energy transfer (LET) reporting in proton radiotherapy: a European multi-centric study. Acta Oncol 2022;61:206-14. [PMID: 34686122 DOI: 10.1080/0284186X.2021.1992007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Høyer M, Grau C, Overgaard J. No time to die - BiGART is back. The 20th Acta Oncologica Symposium - BIGART 2021. Acta Oncol 2022;61:117-9. [PMID: 34991422 DOI: 10.1080/0284186X.2021.2022206] [Reference Citation Analysis]